Accelerator said Oncofactor was its first investment based on internal intellectual property developed at the group.
Accelerator, a corporate venturing-backed biotechnology investment and development company, has backed its 12th start-up with the series A round for Oncofactor, which is trying to treat cancer.
Accelerator said Oncofactor was its first investment based on internal intellectual property developed at the group. The money for the round came from Accelerator’s syndicate partners: Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and WRF Capital.
